Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration

BACKGROUND: The anti-vascular endothelial growth factor (anti-VEGF) injection interval influences treatment burden and compliance in neovascular age-related macular degeneration (nAMD). This real-world study investigates visual acuity (VA), injection-interval extension, central macular thickness (CM...

Descripción completa

Detalles Bibliográficos
Autores principales: Coney, Joseph M., Zubricky, Ryan, Sinha, Samriddhi Buxy, Sonbolian, Nina, Zhou, Lujia, Hull, Thomas P., Lewis, Shawn A., Miller, David G., Novak, Michael A., Pendergast, Scott D., Pham, Hang, Platt, Sean M., Rao, Llewelyn J., Schartman, Jerome P., Singerman, Lawrence J., Donkor, Richard, Fink, Margaret, McCoy, Jasmyne, Karcher, Helene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891747/
https://www.ncbi.nlm.nih.gov/pubmed/36726178
http://dx.doi.org/10.1186/s40942-023-00445-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891747/
https://www.ncbi.nlm.nih.gov/pubmed/36726178
http://dx.doi.org/10.1186/s40942-023-00445-0

Ejemplares similares